#1

Eric Verdin, MD, is the president and CEO of the Buck Institute for Research on Aging; a professor at the Leonard Davis School of Gerontology at the University of Southern California; and a professor at the University of California, San Francisco.

Dr. Verdin discusses several breakthroughs, including:

  • How we can change our own personal rate of aging
  • Rapamycin as an example of a modulator of aging rate
  • Aging is the largest risk factor for non-communicable diseases
  • The need for healthcare to be reinvented as proactive care, not just sick care
  • The relative unimportance of our genetics to how well we age
8 Likes
#2

I think Dr. Verdin is pointing the Buck Institute in the right direction, studying interventions that can be used soon or now to extend healthspan and lifespan. I don’t agree with all of this diet advice, but that’s par for the course. In general, he gives solid, mainstream advice while the Buck does more cutting edge research.

2 Likes
#3

‘We know that only one in twenty people who are on a statin actually benefit from it.’ ‘https://www.youtube.com/watch?v=rwl-qSSNOyI&t=730s’

1 Like
#4

I missed that the first time. Thanks. Is he referring to “number needed to treat”?

In my interview with Nathan Price (now of Thorne), he said variability in gut microbiome affected the effectiveness of statins. That said, don’t cardiologists look at apoB or LDL to see if the statin is working?

Does anyone know what study (“we know”) Verdin is referring to?

1 Like
#5

The NNT does go down with continued treatment years in the studies though.

#6

A very interesting YouTube video in case you missed it. This is the first time I have seen a company trying to commercialize an anti-aging strategy and provide it to everyone at the lowest possible cost. Their product is in phase 1&2 trials. Their main theory if I got it right is modulation of the immune system is the key to longevity. I hope their trial succeeds and they get their product to market as soon as possible at an affordable price.

In the meantime, we have rapamycin as an immune system modulator.

The Company Website:

8 Likes
Stem cells, immune function and Secretome - Discussion
#7

NNT can be very misleading. Not helpful in isolation.

2 Likes
#8

Thanks for finding this. This is great. Interesting that Peter Diamandis is connected to the company. Sounds like a really interesting product. Agreed, I hope the trial succeeds and they can get it to the masses quickly.

3 Likes
#9

Great interview with the CEO of Immunis. Very excited to see where this goes.

4 Likes
#10

You really believe that if successful it will go to masses for an affordable price?

#11

I have no idea.
Every day we read about or see some news of an “Important Breakthrough”.
Mostly hype. Other than rapamycin where are they?

2 Likes
#12

On average we get about 1 “miracle” drug per decade that lowers mortality from a specific cause and also has a trend to decreased acm (sometimes even statistically significantly so).

1 Like
#13

They do sell there products outside of the USA.

Far from “affordable” for the general public.

In my view


Affordable is a few hundred per injection.

Correction and update, used an AI search engine

“Cost of Immunis Treatment”

“Based on available information, Immunis treatment costs are extremely high, exceeding $100,000 per patient. This is due to the complex manufacturing process, which takes over three weeks to complete, resulting in a high processing cost of around $60,000 per patient. Additionally, pharmaceutical companies justify these costs by highlighting the value of Immunis drugs and continued investment in research and development.”

“Note: These figures are based on available data and may vary depending on individual circumstances and insurance plans.”

How many are going to pay $100k for treatment?

1 Like
#14

I don’t think this is correct. I can’t find the talk, but Hans Keirstand has specifically said that they’ve already scaled this and the final product will be very affordable. He’s mentioned it several times. That said, once big Pharma gets hold of it, they’ll be charging us out the ass.

#15

Yes, I heard the same presentation{which is not the one post]. In that same video I recall him saying it was available outside the US.

As I stated it was a basics simple search using an AI search engine.

If the clinic if FL that offer “hyperbaric oxygen treatment” charges if I recall $60K for a series of treatment.

Exosomes{produced from human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs)] are the the $1000 to $3000 per vile range{this is just for the material] depending on the amount of Exosomes. Plus the fee / cost of consultation and injection.

I do not see this as being an “affordable” treatment for the general public/average person.

What do you consider “affordable” for the general public,?

#16

My understanding is that Immunis is not available anywhere. It’s currently in phase 2a trials and is not for sale. Maybe we’re talking about a different thing? Aviv clinics run HBOT treatments out of Florida. but I don’t believe there’s a connection.

1 Like
#17

Some more good news on Immunis. The FDA has granted them phase II trial approval. The indication is incredibly interesting. I hope this moves quickly.

4 Likes